|
gptkbp:instanceOf
|
government agency
|
|
gptkbp:approves
|
gptkb:U.S._Food_and_Drug_Administration
|
|
gptkbp:associatedWith
|
gptkb:Guillain-Barré_syndrome
thrombosis with thrombocytopenia syndrome
|
|
gptkbp:brand
|
gptkb:Janssen
|
|
gptkbp:clinicalTrials
|
over 40,000
Phase 3
|
|
gptkbp:contraindication
|
fatigue
headache
muscle pain
nausea
fever
|
|
gptkbp:developedBy
|
gptkb:Johnson_&_Johnson
|
|
gptkbp:diseaseResistance
|
100%
|
|
gptkbp:distribution
|
global
|
|
gptkbp:drugInterdiction
|
1
|
|
gptkbp:emergencyServices
|
2021
|
|
gptkbp:evaluates
|
approximately 66% in preventing moderate to severe COVID-19
|
|
gptkbp:expansion
|
Yes
|
|
gptkbp:firstAwarded
|
March 2021
|
|
gptkbp:foughtAgainst
|
100%
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Janssen COVID-19 Vaccine
|
|
gptkbp:isIncorporatedIn
|
85% or higher
|
|
gptkbp:marketSegment
|
ongoing
|
|
gptkbp:notable_player
|
single-dose vaccine
|
|
gptkbp:produces
|
gptkb:United_States
|
|
gptkbp:providesSupportFor
|
limited supply in early 2021
|
|
gptkbp:safetyFeatures
|
V-safe program
|
|
gptkbp:storage
|
2 to 8 degrees Celsius
|
|
gptkbp:suitableFor
|
gptkb:CDC
WHO
|
|
gptkbp:targets
|
adults 18 years and older
|
|
gptkbp:technology
|
adenoviral vector technology
|
|
gptkbp:type
|
viral vector vaccine
|